Global Information
회사소개 | 문의 | 비교리스트

세계의 종양 특이 항원 시장

Global Tumor-specific Antigen Market

리서치사 BCC Research
발행일 2019년 05월 상품 코드 845211
페이지 정보 영문 140 Pages
가격
US $ 2,750 ₩ 3,319,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,300 ₩ 3,983,000 PDF (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,960 ₩ 4,779,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,752 ₩ 5,735,000 PDF (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 종양 특이 항원 시장 Global Tumor-specific Antigen Market
발행일 : 2019년 05월 페이지 정보 : 영문 140 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 종양 특이 항원 시장은 2018년 18억 달러에서 2023년까지 24억 달러까지 확대될 것으로 예측되며, 2018-2023년간 6.2%의 연평균 복합 성장률(CAGR)이 전망됩니다.

세계의 종양 특이 항원(Tumor-specific Antigen) 시장을 조사했으며, 시장 개요, 시장 동향 분석과 예측, 부문 및 지역별 분석과 예측, 암 연구에 대한 정부의 규제 체계·정책·자금 계획 및 주요 기업 개요 등의 정보를 제공합니다.

제1장 서론

제2장 요약 및 하이라이트

제3장 시장 및 기술 배경

  • 시장 개요
  • 시장 잠재성
  • 투자 분석
  • 규제 프레임워크
  • 산업 성장 촉진요인

제4장 종양 특이 항원 시장 : 분류별

  • 종양 태아
  • 종양 바이러스
  • 과다 발현/축적
  • CT9/CT10
  • 돌연변이
  • 계통 한정 항원
  • 유전자형(Idiotypic)
  • 기타

제5장 종양 특이 항원 시장 : 소스별

  • 코딩 영역
  • 비코딩 영역

제6장 종양 특이 항원 시장 : 용도별

  • 진단
  • Drug Discovery & Development
  • 치료
  • 위험 평가
  • 예후
  • 임상 및 기초 연구

제7장 종양 특이 항원 시장 : 지역별

  • 북미
  • 유럽
  • 아시아태평양
  • 기타

제8장 종양 특이 항원 시장 구조

  • 산업 구조
  • 시장 혁신
  • 경쟁 분석

제9장 기업 개요

  • ABCAM PLC
  • AGILENT TECHNOLOGIES INC.
  • AIVITA BIOMEDICAL
  • BBI GROUP
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES INC.
  • BRIGHTPATH BIOTHERAPEUTICS
  • CARIS LIFE SCIENCES INC.
  • CISBIO BIOASSAYS
  • CREATIVE DIAGNOSTICS
  • ELI LILLY AND CO.
  • ENZO BIOCHEM INC.
  • EXTERNAUTICS
  • F. HOFFMANN-LA ROCHE LTD.
  • GO THERAPEUTICS
  • JANSSEN GLOBAL SERVICES LLC
  • LEE BIOSOLUTIONS INC.
  • MERCK MILLIPORE
  • MESO SCALE DIAGNOSTICS, LLC
  • PERKINELMER INC.
  • QUEST DIAGNOSTICS
  • SIGNOSIS INC.
LSH 19.05.24

List of Tables

  • Summary Table: Global Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 1: Investment Analysis
    • Table 2: Biomarkers for Cancer Detection, Diagnosis and Prognosis
    • Table 3: Protein Arrays: Cancer Biomarker Discovery
    • Table 4: Global Prevalence of Cancer, by Type, 2016
    • Table 5: Regional Cancer Prevalence, by Type, 2015 and 2016
    • Table 6: Investment in Cancer, by Area of Research, 2017
    • Table 7: Investments in Cancer-Based Research, 2016-2018
    • Table 8: Molecular Targeted Therapy in Anticancer
    • Table 9: CAR Target Antigen for Hematologic Malignancies and Potential Off-Tumor Targets
    • Table 10: Global Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 11: Tumor Antigen
    • Table 12: Global Market for Oncofetal Antigen, by Region, Through 2023
    • Table 13: Pharmaceutical and Bioinformatic Partnerships and Alliances
    • Table 14: Global Market for Oncoviral Antigen, by Region, Through 2023
    • Table 15: U.S. R&D Funding for Basic Research
    • Table 16: Global Market for Overexpressed/Accumulated Antigen, by Region, Through 2023
    • Table 17: Investment in Cancer, by Research Area
    • Table 18: Global Market for CT9/CT10 Antigen, by Region, Through 2023
    • Table 19: Regional Cancer Prevalence, by Type, 2015 and 2016
    • Table 20: Global Market for Mutated Antigen, by Region, Through 2023
    • Table 21: Global Leukemia Deaths, 2016
    • Table 22: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
    • Table 23: Global Market for Lineage Restricted Antigen, by Region, Through 2023
    • Table 24: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
    • Table 25: Global Prevalence of Cancer, by Type, 2016
    • Table 26: Global Cancer Mortalities, by Type, 2016
    • Table 27: Global Market for Idiotypic-Based Antigen, by Region, Through 2023
    • Table 28: Clinical Trials in Idiotypic
    • Table 29: Identified Post-Translationally Modified AutoAntigen
    • Table 30: Global Market for Other Antigen, by Region, Through 2023
    • Table 31: Global Prevalence of Diabetes, 2017 and 2045
    • Table 32: Global Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 33: Tumor and Tissue-Specific Promoters Used to Generate Tumor-specific Antigen Sourced Through Coding Region
    • Table 34: Global Market for Coding Region-Based Antigen, by Region, Through 2023
    • Table 35: Global Market for Non-Coding Region-Based Antigen, by Region, Through 2023
    • Table 36: Global Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 37: Key Immunological Techniques for Diagnosis of Cancer
    • Table 38: Global Market for Tumor-specific Antigen in Diagnostic Applications, by Region, Through 2023
    • Table 39: Circulating Antigen and Immunodiagnosis of Cancer
    • Table 40: Global Market for Tumor-specific Antigen in Drug Discovery and Development Applications, by Region, Through 2023
    • Table 41: Clinical Trials Involving Tumor-specific Antigen for Cancer Therapeutics
    • Table 42: Global Market for Tumor-specific Antigen in Therapeutic Applications, by Region, Through 2023
    • Table 43: Global Market for Tumor-specific Antigen in Risk Assessment Applications, by Region, Through 2023
    • Table 44: Global Market for Tumor-specific Antigen in Prognostic Applications, by Region, Through 2023
    • Table 45: Global Prevalence of Different Cancers, by Country, 2016
    • Table 46: Deaths from Different Cancer Type, by Country, 2016
    • Table 47: NCI Funding, 2012-2017
    • Table 48: Global Market for Tumor-specific Antigen in Clinical and Basic Research Applications, by Region, Through 2023
    • Table 49: North American Market for Tumor-specific Antigen, by Country, Through 2023
    • Table 50: North American Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 51: U.S. Funding for Cancer Research, by Type, 2015 and 2016
    • Table 52: North American Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 53: U.S. Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 54: Canadian Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 55: North American Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 56: European Market for Tumor-specific Antigen, by Country/Region, Through 2023
    • Table 57: European Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 58: Cancer Prevalence in the U.K., by Country, 2015 and 2020
    • Table 59: European Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 60: U.K. Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 61: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
    • Table 62: French Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 63: German Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 64: Ongoing Cancer-Based Trials in Germany
    • Table 65: Cancer Cases in Spain, 2012 and 2015
    • Table 66: European Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 67: Spanish Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 68: Projects Recommended to the NCU Board for Funding, 2016
    • Table 69: Rest of European Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 70: Asia-Pacific Market for Tumor-specific Antigen, by Country/Region, Through 2023
    • Table 71: Asia-Pacific Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 72: Cancer Incidence in China, 2016
    • Table 73: Asia-Pacific Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 74: Chinese Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 75: Clinical Trials for Cancer
    • Table 76: Indian Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 77: Asia-Pacific Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 78: Japanese Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 79: Australian Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 80: Change in Cancer Prevalence in Other APAC Countries, 2005-2016
    • Table 81: Rest of APAC Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 82: Clinical Trials for Tumor-specific Antigen: Singapore
    • Table 83: RoW Market for Tumor-specific Antigen, by Region, Through 2023
    • Table 84: Cancer Incidence in Brazil, 2016
    • Table 85: Latin American Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 86: RoW Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 87: Causes of Death in Argentina and Percentage Change, 2005-2016
    • Table 88: RoW Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 89: RoW Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 90: Cancer Prevalence in Kenya, by Type, 2015 and 2016
    • Table 91: Middle Eastern and African Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 92: Global Suppliers of Tumor-specific Antigen Market
    • Table 93: Selected Tumor-specific Antigen Companies
    • Table 94: Cancer Antigen for Clinical Trials, as of January 2019
    • Table 95: Product Launches, Product Development and FDA Clearance
    • Table 96: Notable Mergers and Acquisitions
    • Table 97: Notable Agreements, Collaborations and Partnerships
    • Table 98: Notable Funding, Expansion and Divestment
    • Table 99: Abcam PLC: Product Portfolio
    • Table 100: Abcam PLC: Recent Developments
    • Table 101: Agilent Technologies Inc.: Product Portfolio
    • Table 102: Agilent Technologies Inc.: Recent Developments
    • Table 103: AIVITA Biomedical: Product Portfolio
    • Table 104: AIVITA Biomedical: Recent Developments
    • Table 105: BBI Group: Product Portfolio
    • Table 106: Biomerieux SA: Product Portfolio
    • Table 107: Bio-Rad Laboratories Inc.: Product Portfolio
    • Table 108: Bio-Rad Laboratories Inc.: Recent Developments
    • Table 109: BrightPath Biotherapeutics: Product Portfolio
    • Table 110: BrightPath Biotherapeutics: Recent Developments
    • Table 111: Caris Life Sciences Inc.: Product Portfolio
    • Table 112: Caris Life Sciences Inc.: Recent Developments
    • Table 113: Cisbio Bioassays: Product Portfolio
    • Table 114: Creative Diagnostics: Product Portfolio
    • Table 115: Creative Diagnostics: Recent Developments
    • Table 116: Eli Lilly and Co.: Product Portfolio
    • Table 117: Eli Lilly and Co.: Recent Developments
    • Table 118: Enzo Biochem Inc.: Product Portfolio
    • Table 119: Enzo Biochem Inc.: Recent Developments
    • Table 120: Externautics: Product Portfolio
    • Table 121: F. Hoffmann-La Roche Ltd.: Product Portfolio
    • Table 122: F. Hoffmann-La Roche Ltd.: Recent Developments
    • Table 123: GO Therapeutics: Product Portfolio
    • Table 124: GO Therapeutics: Recent Developments
    • Table 125: Janssen Global Services LLC: Product Portfolio
    • Table 126: Janssen Global Services LLC: Recent Developments
    • Table 127: Lee Biosolutions Inc.: Product Portfolio
    • Table 128: Merck Millipore: Product Portfolio
    • Table 129: Merck Millipore: Recent Developments
    • Table 130: Meso Scale Diagnostics, LLC: Product Portfolio
    • Table 131: Meso Scale Diagnostics, LLC: Recent Developments
    • Table 132: PerkinElmer Inc.: Product Portfolio
    • Table 133: PerkinElmer Inc.: Recent Developments
    • Table 134: Quest Diagnostics: Product Portfolio
    • Table 135: Quest Diagnostics: Recent Developments
    • Table 136: Signosis Inc.: Product Portfolio

List of Figures

  • Summary Figure: Global Market for Tumor-specific Antigen, by Source, 2017-2023
    • Figure 1: Regional Prevalence of Cancer, 2015-2016
    • Figure 2: Global Prevalence of Cancer, by Type, 2016
    • Figure 3: Targeting of Tumor-specific Mutated Antigen in T-Cell Immunotherapy
    • Figure 4: Global Leukemia Deaths, 2016
    • Figure 5: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
    • Figure 6: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
    • Figure 7: Global Prevalence of Cancer, by Type, 2016
    • Figure 8: Global Cancer Mortalities, by Type, 2016
    • Figure 9: Determination of Antibody Idiotype
    • Figure 10: Global Prevalence of Diabetes, 2017 and 2045
    • Figure 11: Sources of Tumor-specific Antigen
    • Figure 12: Key Applications: Tumor-specific Antigen
    • Figure 13: Drug Discovery Cycle
    • Figure 14: Clinical Cancer Research for Therapeutic Applications
    • Figure 15: The Role of Prognostic and Predictive Markers in Individualized Treatment
    • Figure 16: Global Prevalence of Different Cancers, by Country, 2016
    • Figure 17: Deaths from Different Cancer Type, by Country, 2016
    • Figure 18: NCI Funding, 2012-2017
    • Figure 19: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
    • Figure 20: Cancer Incidence in China, 2016
    • Figure 21: Major Breakthroughs in Cancer Research: India
    • Figure 22: Cancer Prevalence in Kenya, by Type, 2015 and 2016
    • Figure 23: Tumor-specific Antigen Industry Structure
    • Figure 24: Tumor-specific Antigen Development Flow Chart

Report Highlights:

The global market for tumor-specific antigen should grow from $1.8 billion in 2018 to $2.4 billion by 2023 at a compound annual growth rate (CAGR) of 6.2% for the period of 2018-2023.

Non-Coding region market for tumor-specific antigen should grow from $1.2 billion in 2018 to reach $1.7 billion by 2023 at a CAGR of 6.4% for the period of 2018-2023.

Coding region market for tumor-specific antigen should grow from $589.6 million in 2018 to reach $777.8 million by 2023 at a CAGR of 5.7% for the period of 2018-2023.

Report Scope:

The scope of this report is broad and covers category, source and applications of Tumor-specific Antigen. The market has been segmented by source into coding region and Non-Coding region. Revenue forecasts from 2017 to 2023 are given for each segment and regional market with estimated value derived from the revenue of manufacturers.

The report also includes a discussion of the major players across each region of the Tumor-specific antigen market. Further, it explains the major drivers and regional dynamics of the global Tumor-specific antigen market and current trends within the industry.

The report concludes with a special focus on vendor landscape and includes detailed profiles of the main vendors in the Tumor-specific antigen market.

Report Includes:

  • 75 data tables and 61 additional tables
  • An overview of the global market for tumor-specific antigen
  • Analyses of global market trends, with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Coverage of various types of product available in the tumor-specific antigen market and discussion of their potential applications
  • Information on oncofetal, oncoviral, overexpressed/accumulated, mutated, lineage restricted and idiotypic tumor-specific antigens and discussion of their specific targets
  • Insights into regulatory framework and policies and funding initiatives by the government for cancer research
  • A look into advancements in antigen specific T-Cell therapy for cancer and innovation within the industry
  • Detailed profiles of the major vendors in the global tumor-specific antigen market including Agilent Technologies Inc., AIVITA Biomedical, Eli Lilly and Co., GO Therapeutics and Merck Millipore

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Market Overview
  • Market Potential
  • Investment Analysis
  • Regulatory Framework
    • United States
    • European Union
    • Australia
    • Japan
    • India
    • China
  • Industry Growth Drivers
    • Surging Demand for Potential Cancer Biomarker Candidates
    • Rising Prevalence of Cancer
    • Increasing Investments in Cancer Diagnosis and Research
    • Rising Focus on Developing Targeted Therapies
    • Antigen Specific T-Cell Therapy

Chapter 4: Tumor-specific Antigen Market by Category

  • Oncofetal
  • Oncoviral
  • Overexpressed/Accumulated
  • CT9/CT10
  • Mutated
  • Lineage-Restricted Antigen
  • Idiotypic
  • Others

Chapter 5: Tumor-specific Antigen Market by Source

  • Coding Region
  • Non-Coding Region
    • Growing the Background of Immunotherapy Targets

Chapter 6: Tumor-specific Antigen Market by Application

  • Diagnostics
  • Drug Discovery and Development
  • Therapeutics
  • Risk Assessment
  • Prognostics
  • Clinical and Basic Research

Chapter 7: Tumor-specific Antigen Market by Region

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • France
    • Germany
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • Middle East and Africa

Chapter 8: Tumor-specific Antigen Market Industry Structure

  • Industry Structure
    • Procurement of Raw Materials
    • Manufacturing/Development Process
    • End-Users
  • Innovation in the Market
  • Competitive Analysis

Chapter 9: Company Profiles

  • ABCAM PLC
  • AGILENT TECHNOLOGIES INC.
  • AIVITA BIOMEDICAL
  • BBI GROUP
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES INC.
  • BRIGHTPATH BIOTHERAPEUTICS
  • CARIS LIFE SCIENCES INC.
  • CISBIO BIOASSAYS
  • CREATIVE DIAGNOSTICS
  • ELI LILLY AND CO.
  • ENZO BIOCHEM INC.
  • EXTERNAUTICS
  • F. HOFFMANN-LA ROCHE LTD.
  • GO THERAPEUTICS
  • JANSSEN GLOBAL SERVICES LLC
  • LEE BIOSOLUTIONS INC.
  • MERCK MILLIPORE
  • MESO SCALE DIAGNOSTICS, LLC
  • PERKINELMER INC.
  • QUEST DIAGNOSTICS
  • SIGNOSIS INC.
Back to Top
전화 문의
F A Q